2022年中国乳腺癌重要临床试验成果及最新进展  

Progress of important clinical trials of breast cancer in China in 2022

作　　者：邵志博 杨犇龙 吴炅 SHAO Zhibo;YANG Benlong;WU Jiong(Department of Breast Surgery,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Collaborative Innovation Center for Cancer Medicine,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海200032 [2]中国上海肿瘤医学协同创新中心,上海200032

出　　处：《中国癌症杂志》2023年第2期103-109,共7页China Oncology

摘　　要：乳腺癌已经成为全球发病率最高的恶性肿瘤,严重危害广大女性的身心健康,对于临床肿瘤的防治也是一个巨大挑战。随着对乳腺癌发病、转移机制研究的深入,以及多组学技术和肿瘤免疫等转化研究的发展,已经证明乳腺癌是一种分子分型和临床特征高度异质性的肿瘤,不同亚型乳腺癌临床治疗方式既有差异又存在联系,乳腺癌临床研究领域的成果层出不穷。2022年,针对不同亚型乳腺癌均有重要的临床试验成果。在人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌的新辅助治疗方面,PHEDRA研究为患者提供了新的治疗选择;对于HER2阳性转移性乳腺癌,PHILA研究和SYSUCC-002研究结果为临床医师提供了参考;而对于脑转移的患者,PERMEATE研究显示,吡咯替尼联合卡培他滨方案有望成为HER2阳性脑转移人群,尤其是未经局部放疗的脑转移患者的优选治疗方案。在激素受体阳性乳腺癌中,阿贝西利、达尔西利、瑞波西利等药物的多项临床研究(monarchE研究、DAWNA-1研究、MONALEESA系列研究等)证实了其对内脏转移的疗效。对于三阴性乳腺癌,亦有多项临床试验正在进行中。本文就过去的一年中乳腺癌治疗领域临床研究的新进展进行回顾。Breast cancer has become the most common type of cancer in the world,harming the majority of women's physical and mental health and challenging clinical prevention and treatment of tumors.With the in-depth research on the pathogenesis and metastasis mechanism of breast cancer,as well as the development of translational research such as multiomics technology and tumor immunity,it has been proved that breast cancer has highly heterogeneous molecular and clinical characteristics.The clinical treatment methods of different subtypes of breast cancer are different and related,and the achievements in the field of breast cancer clinical research are fruitful.In 2022,results of important clinical trials have achieved for different subtypes of breast cancer.For the neo-adjuvant treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer,the PHEDRA study provided new adjuvant treatment options for HER2 positive breast cancer patients;And for the HER2 positive metastatic breast cancer,PHILA study and SYSUCC-002 study results provided reference for clinicians.For patients with brain metastasis,PERMEATE study showed that pyrrolitinib combined with capecitabine regimen was to become the preferred treatment scheme for HER2 positive brain metastasis population,especially for patients with brain metastasis without local radiotherapy.In hormone receptor positive breast cancer,a number of clinical trials(monarchE study,DAWNA-1 study,MONALEESA series of studies,etc.)of arbacilli,daracilli,rebosilli and others reported their efficacy on visceral metastasis.For triple-negative breast cancer,many clinical trials are under way.This paper aimed to review the recent advances in clinical research on breast cancer in the past year.

关 键 词：乳腺癌 临床试验 重要成果 人表皮生长因子受体2 激素受体 三阴性乳腺癌 靶向治疗 化疗 联合治疗 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]